Editas Medicine Secures Approval for Gene Editing Trial in Hyperlipidemia

Editas Medicine has received approval to start a Phase 1/2 clinical trial in Australia for EDIT-401, a gene-editing therapy for Heterozygous Familial Hypercholesterolemia (HeFH). This experimental treatment aims to lower LDL-cholesterol levels by increasing LDLR protein expression. Patient dosing is expected to begin this year, with initial safety data anticipated in Q1 2027, marking a step forward in gene therapy for genetic cholesterol disorders.